Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NeoTX, MedImmune Announce Clinical Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

NeoTX, MedImmune Announce Clinical Collaboration

To support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI

By: Betsy Louda

, Contract Pharma

Active Biotech’s partner, NeoTX, has entered a clinical collaboration with AstraZeneca Group’s global biologics research and development arm, MedImmune, to support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca’s IMFINZI. 

 
IMFINZI (durvalumab) is a human monoclonal antibody that blocks the immune checkpoint protein programmed death-ligand (PD-L1). Under terms of the agreement, NeoTX and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in solid tumors. NeoTX will sponsor the study, while AstraZeneca will supply durvalumab. Up to 195 patients are planned to be enrolled in this multicenter, open-label study, which is planned to start during 2019.

“We are very pleased with NeoTX’s progress in the ANYARA project. The collaboration with AstraZeneca validates the project and is an important step towards start of the clinical study” says Helén Tuvesson, chief executive officer, Active Biotech AB.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics